Advancing the commercialization readiness for a robust, 3D printed titanium, myoelectric powered prosthetic digit system

Active Grant Awarded

Award ID
SB1EB038130
Recipient
Awarding agency
Obligated
$362,530

Award facts

Completion date 12% complete
Place of performance
Baltimore, MD 21202, USA

Award details come from USAspending.gov.

About this award

The National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering awarded Infinite Biomedical Technologies, LLC (doing business as I.b.t.) $362,530 in grant funding on August 24, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award funds a commercialization readiness pilot for the Point Powered, a 3D-printed titanium, myoelectric-powered prosthetic digit for individuals with partial hand limb loss. The pilot delivers late-stage technical assistance in optimizing manufacturing processes to prepare the device for scaled production.

The Point Powered project builds on Phase I work (R43EB030895) that engineered the frame, transmission, and motor driver. Phase II (R44EB030895) is ongoing and focuses on a novel clutch design and a rechargeable power system. The award's ultimate completion date is August 31, 2028, and work is performed in Baltimore, Maryland (ZIP 21202). The assistance type is a grant, and the full $362,530 is obligated.

Description

Abstract
Approximately 700,000 people live with partial hand limb loss (PHLL) in the united states, with an estimated 50,000 new partial hand amputations every year. Despite the advances in miniaturized electronics and motors, there has been very little advancement in mechatronic prosthetic digits for this underserved patient population. In fact, to date, there is only one myoelectric prosthetic option for individuals with PHLL in the US. This option is fragile, often limited to light-duty tasks, and is too large to use on most partial hand loss cases. Considering this, IT is no surprise that less than half of the individuals with partial hand absence are able to return to their previous employment, and those who do must often make considerable changes to their work-related tasks. Thus, our team set out to create the point powered, a durable myoelectric prosthesis for individuals with PHLL that is better suited for heavy duty tasks. Phase I of the project (R43EB030895) was focused on engineering development of a frame, transmission, and motor driver. Phase II effort (R44EB030895) is ongoing and focused on two key features of the powered prosthesis: a novel clutch design and rechargeable power system. The clutch is important since IT will enable the finger to tolerate a 10-fold increase in passive load transmission versus during active use. The rechargeable power system is in response to a user needs analysis we conducted that produced two main requirements: 1) low profile design; and 2) compatible with single-handed use. As development progresses, components must undergo late-stage activities to prepare for scaled production and develop necessary support for patients and clinicians post-launch. We propose this commercialization readiness pilot to fund late-stage technical assistance in the form of optimizing manufacturing processes and building infrastructure to support device adoption through the development of an accelerated fitting and training program. The mission of our collaborative group is to help individuals with PHLL regain the abilities that they had previously lost. We develop products that provide prosthetists and patients with solutions to meet the unique needs of each patient in this dynamic and challenging healthcare setting. To date, we have served over 2,400 individuals with partial hand limb loss. The work outlined in this proposal is critical to our efforts to commercialize the point powered and create infrastructure to get devices to patients faster and with in-depth, personalized training. We believe that this technology will provide an effective and durable solution for many people with finger loss and ensure their ability to enjoy their work, family, and life to the fullest.

Quick answers

Who received award SB1EB038130?

SB1EB038130 was awarded to Infinite Biomedical Technologies, LLC by National Institute of Biomedical Imaging and Bioenginering (National Institutes of Health) on August 24, 2026.

How much is award SB1EB038130 worth?

$362,530 has been obligated on SB1EB038130.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award